CONDOR Phase 3: Brolucizumab Superior to PRP in Proliferative Diabetic Retinopathy
Key Questions
What were the key efficacy results from the CONDOR Phase 3 trial?
In the CONDOR Phase 3 trial published in JAMA, brolucizumab administered every 12 weeks resulted in a mean BCVA gain of +0.2 letters compared to a loss of -4.2 letters with panretinal photocoagulation (PRP) at week 54. Additionally, 64% of brolucizumab-treated patients were free of proliferative diabetic retinopathy (PDR) versus 22% with PRP, with 33% fewer vision-threatening complications.
How does brolucizumab challenge the standard treatment for proliferative diabetic retinopathy?
Brolucizumab demonstrates superiority over PRP, the current standard, in maintaining vision and reducing PDR progression, aligning with anti-VEGF durability in diabetic retinopathy and PDR. This may lead to a potential shift in treatment guidelines.
What were the safety findings with brolucizumab in the CONDOR trial?
The trial reported low adverse events, with intraocular inflammation (IOI) occurring in only 5% of patients. Overall, brolucizumab showed a favorable safety profile compared to PRP.
Ph3 JAMA-published: brolucizumab q12w +0.2L vs -4.2L BCVA vs PRP wk54, 64% PDR-free vs 22%, 33% fewer vision threats, low AEs (5% IOI). Challenges PRP standard, aligns with anti-VEGF durability in DR/PDR; potential guideline shift.